Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

PHASE3RecruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

October 2, 2013

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Gastric Cancer, Adjuvant Chemotherapy, XO
Interventions
DRUG

Docetaxel and capecitabine and oxaliplatin

Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1

DRUG

capecitabine and oxaliplatin

Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Inha University Hospital

OTHER

collaborator

Hallym University Medical Center

OTHER

lead

Asan Medical Center

OTHER

NCT01935778 - Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH | Biotech Hunter | Biotech Hunter